Nitin Jain, MD, on Implications of Using Ibrutinib Plus Venetoclax in the Front-Line Setting and Beyond

Posted: Friday, January 10, 2020

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses the implications of using ibrutinib plus venetoclax in the front-line treatment of chronic lymphocytic leukemia and how that same treatment is likely to evolve in second-line or later therapies.